Business

James Rules Out Rebuild, Demands Championship Contention in Year 24

Published

57 minutes ago

22 May 2026

LOS ANGELES — LeBron James has made it clear that he will only consider teams positioned for immediate championship contention as he prepares for his 24th NBA season, ruling out any involvement in rebuilding projects.

The 41-year-old superstar, who turns 42 in December, has not yet made a final decision on his future but is expected to inform the Los Angeles Lakers of his plans before the NBA Draft in late June. James exercised his $52.6 million player option for the 2025-26 season and will enter unrestricted free agency this summer.

Multiple sources confirm James is prioritizing winning above all else. He has shown no interest in joining franchises focused on long-term rebuilding, emphasizing his desire to compete for a fifth NBA title.

James has won four championships with three different teams — two with the Miami Heat (2012, 2013), one with the Cleveland Cavaliers (2016), and one with the Lakers (2020). He remains highly productive, averaging 20.9 points, 6.1 rebounds, and 7.2 assists per game in the 2025-26 season.

The Lakers are considered strong contenders to retain him, especially with Luka Doncic already on the roster. However, James has not committed to any specific outcome. His agent, Rich Paul of Klutch Sports, has remained silent on the matter.

James has a history of deliberate free agency decisions. He is unlikely to accept the veteran minimum but may take less than the maximum to help a contender build a stronger roster around him.

The Lakers hold Bird Rights and have significant cap flexibility. Their ability to surround James and Doncic with complementary talent will be a major factor in his decision.

James has spent the past six seasons with the Lakers after previous stints with the Cavaliers and Heat. His longevity continues to impress, as he ranks among the league’s top performers despite his age.

No official announcement has been made. James has focused on family and business interests while evaluating his options for the upcoming season.

The upcoming NBA Draft and free agency period will be pivotal. Several contending teams are monitoring the situation, though James has shown loyalty to the Lakers while keeping his options open.

James has not publicly commented on specific teams or contract details since the end of the 2025-26 season. His emphasis on championship contention remains the central theme of his decision-making process.

Business

Euronet Worldwide, Inc. (EEFT) Analyst/Investor Day Transcript

Published

53 seconds ago

23 May 2026

NewsAdmin

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Euronet Worldwide, Inc. (EEFT) Analyst/Investor Day May 20, 2026 10:00 AM EDT

Company Participants

Stephanie Taylor – Director of Financial Planning & IR
Michael Brown – Chairman, CEO & President
Martin Bruckner – Senior VP & Chief Technology Officer
Nikos Fountas – Executive VP and CEO of EFT Americas, Middle East & Africa Division
Himanshu Pujara – Senior VP & MD of EFT Asia Pacific & Ren Payments
Kevin Caponecchi – Executive VP and CEO of epay, Software & EFT Asia Pacific Segment
Juan Bianchi – Executive VP & CEO of Money Transfer Segment
Rick Weller – Executive VP, Chief Accounting Officer & CFO

Conference Call Participants

Rayna Kumar – Oppenheimer & Co. Inc., Research Division
Vasundhara Govil – Keefe, Bruyette, & Woods, Inc., Research Division
Charles Nabhan – Stephens Inc., Research Division
Cristopher Kennedy – William Blair & Company L.L.C., Research Division
Darrin Peller – Wolfe Research, LLC
Owen Rickert – Northland Capital Markets, Research Division
Peter Heckmann – D.A. Davidson & Co., Research Division
Andrew Schmidt – KeyBanc Capital Markets Inc., Research Division

Presentation

Stephanie Taylor
Director of Financial Planning & IR

All right. Good morning, and thank you for joining us for Euronet’s 2026 Investor Day. I’d like to thank everybody for joining us here and those of you that are online. I’m Stephanie Taylor. I’m the Corporate Treasurer at Euronet Worldwide, and I oversee the Investor Relations function. We really appreciate you spending the morning with us as we try to — as we’re excited to walk you through where we are as a company, how our business looks today, what our growth opportunities are ahead of us. Many of you have been with us for a long time, and some of you are new to the story, but I’m confident that this session is going to be beneficial for everybody in the room. You’ll hear directly from several members of our management team as we provide a deeper look into the company’s evolution, our

Business

Kuraray Co., Ltd. 2026 Q1 – Results – Earnings Call Presentation (OTCMKTS:KURRY) 2026-05-22

Published

8 minutes ago

23 May 2026

NewsAdmin

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Business

Form 13D/A Genesis Energy For: 22 May

Published

15 minutes ago

23 May 2026

NewsAdmin

Form 13D/A Genesis Energy For: 22 May

Business

Exclusive-US House Foreign Affairs Committee Chair warns of China role in Argentina contract bid

Published

22 minutes ago

22 May 2026

NewsAdmin

Exclusive-US House Foreign Affairs Committee Chair warns of China role in Argentina contract bid

Business

Whole Foods minestrone soup recalled in 17 states over undeclared shrimp

Published

29 minutes ago

22 May 2026

NewsAdmin

Whole Foods minestrone soup recalled in 17 states over undeclared shrimp

Eli Lilly chief scientific and product officer Daniel Skovronsky discusses FDA approval of its new oral GLP-1 drug, a $4.5B manufacturing expansion and Mounjaro becoming the world’s top-selling drug on ‘Mornings with Maria.’

Cups of minestrone soup sold at Whole Foods in 17 states and Washington, D.C. have been recalled over possible “undeclared shrimp” that could cause a life-threatening allergic reaction in certain people, according to the U.S. Food and Drug Administration.

Massachusetts-based company Kettle Cuisine decided this week to recall 24oz cups of Whole Foods Market Kitchen Minestrone Soup.

The minestrone was sold in Whole Foods in Alabama, Connecticut, Washington, D.C., Florida, Georgia, Massachusetts, Maryland, Maine, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, South Carolina, Tennessee, and Virginia.

The soup was also available nationwide through Whole Foods’ and Amazon’s online stores. Amazon owns Whole Foods.

CHOCOLATE-COVERED SNACK PRODUCT SOLD IN 16 STATES RECALLED FOR POTENTIALLY UNDECLARED ALMONDS AND CASHEWS

Close-up of a Whole Foods Market shopping cart with logo visible, Lafayette, California, March 2, 2025. (Photo by Smith Collection/Gado/Getty Images) (Smith Collection/Gado/Getty Images / Getty Images)

The company issued the recall after discovering a single cup of the soup in-store which contained the wrong product and included shrimp.

No illnesses have yet been reported.

Pitctures of the product (FDA / Unknown)

The recalled soup is packaged in a 24-ounce, clear plastic cup that has the Lot Code: 1762181 and, use by 05/27/26 on the top rim of the cup.

Signage at the Whole Foods Market store in San Ramon, California reading “Whole Foods Market and Amazon”, announcing the acquisition of Whole Foods Market by online retailer Amazon, August 28, 2017. On August 28, 2017, Amazon completed its acquisitio (Smith Collection/Gado/Getty Images) / Getty Images)

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

It also has the UPC identifier of 099482502065 on the back label.

Customers can take the soup back for a full refund.

Business

Form 144 10x Genomics For: 22 May

Published

36 minutes ago

22 May 2026

NewsAdmin

Form 144 10x Genomics For: 22 May

Business

Trump joins Lawler to test fiscal pitch in competitive New York district

Published

43 minutes ago

22 May 2026

NewsAdmin

Trump joins Lawler to test fiscal pitch in competitive New York district

Business

Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Published

50 minutes ago

22 May 2026

NewsAdmin

Nurix Therapeutics, Inc. (NRIX) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 1:30 PM EDT

Company Participants

Arthur Sands – CEO, President & Director
Jason Kantor – Chief Business Officer

Conference Call Participants

Brian Abrahams – RBC Capital Markets, Research Division

Presentation

Brian Abrahams
RBC Capital Markets, Research Division

So let’s get started. Good afternoon, everyone. Welcome back from lunch. I’m Brian Abrahams, senior biotech analyst here at RBC Capital Markets. We’re really pleased to have our next featured company, Nurix Therapeutics, represented by their CEO, Arthur Sands and their CBO, Jason Kantor.

Arthur Sands
CEO, President & Director

Great. Good to be here. Thanks, Brian.

Question-and-Answer Session

Brian Abrahams
RBC Capital Markets, Research Division

Thanks for being here. So maybe let’s start a little bit bigger picture on your lead program, Bexdeg. Tell us what your latest view is on the potential advantages that BTK degraders can have in the CLL space relative to the currently available inhibitors, what’s out there today? And what’s been your view as to the strongest preclinical and clinical evidence and data to date that’s really helped support that? And I know the data is continuing to evolve. So I would love to hear your latest views on that.

Arthur Sands
CEO, President & Director

Yes, excellent question. The advantage of targeted protein degrader in this space in CLL and in BTK, we’re seeing advantages expand and grow. So I can tell you where we started and now where we think it is, which is quite exciting.

So we started with the concept that by removing the protein, we could address certain BTK inhibitor resistance mutations, which were just emerging, if you go back to the beginning of, let’s say, 2020, 2019. So the concept that by degrading the protein through the ubiquitous proteasome system, we could address this emerging problem

Business

The Timken Company (TKR) Analyst/Investor Day Transcript

Published

1 hour ago

22 May 2026

NewsAdmin

The Timken Company (TKR) Analyst/Investor Day May 20, 2026 9:00 AM EDT

Company Participants

Neil Frohnapple – Vice President of Investor Relations
Lucian Boldea – CEO, President & Director
John Szarka – Senior VP & Chief Technology Officer
Timothy Graham – Executive VP & President of Industrial Motion
Michael Discenza – Executive VP & CFO

Conference Call Participants

Bryan Blair – Oppenheimer & Co. Inc., Research Division
David Raso – Evercore ISI Institutional Equities, Research Division
Angel Castillo Malpica – Morgan Stanley, Research Division
Robert Wertheimer – Melius Research LLC
Tomohiko Sano – JPMorgan Chase & Co, Research Division
Timothy Thein – Raymond James & Associates, Inc., Research Division
Joseph Ritchie – Goldman Sachs Group, Inc., Research Division
Justin Bergner – Gabelli Funds, LLC
Steve Barger – KeyBanc Capital Markets Inc., Research Division

Presentation

Neil Frohnapple
Vice President of Investor Relations

Good morning, everyone. Welcome to the Timken Company’s 2026 Investor Day. My name is Neil Frohnapple, Vice President of Investor Relations for Timken. We’re excited to have many with us here in the room today in New York City, and we welcome those who are joining us virtually via webcast. We appreciate everyone taking the time to learn more about how Timken intends to elevate its performance.

Let’s start by taking a look at the agenda. This morning, you’ll hear from our President and CEO, Lucian Boldea, who will give you an overview of Timken’s strategic plan to accelerate profitable growth and structurally increase margins. Then our Chief Technology Officer, John Szarka will spend time discussing how Timken’s innovation and technology will support our growth in the next generation of motion systems. After John speaks, we’ll take a short break, and then our President of Industrial Motion, Tim Graham will take you through how we’re winning with customers and creating value as One Timken. Our final presentation today will be from Mike Discenza, Executive Vice President and CFO, as he shares more details